menu
    • menu
    [{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PiN-21","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"The University of Pittsburgh School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PittCoVacc","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"The University of Pittsburgh School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ab8","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"PDX1\/MAFA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genprex","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Genprex"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"GPX-002","moa":"PDX1\/MAFA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ National Institutes of Health"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"PDX1\/MAFA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genprex","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Genprex"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SNAP CAR T-cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Coeptis Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"The University of Pittsburgh School of Medicine \/ Coeptis Therapeutics"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"The University of Pittsburgh School of Medicine \/ Astellas Pharma"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"CSL Behring","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ CSL Behring"}]

    Find Clinical Drug Pipeline Developments & Deals by The University of Pittsburgh School of Medicine

    Menu

    The University of Pittsburgh School of Medicine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNAP CAR T-cell

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Coeptis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Techn...

                            Details : Companies are expanding this agreement to include engineering of NK cells to generate SNAP-CAR NK therapies, to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including HER2-expressing cancer.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 10, 2023

                            Lead Product(s) : SNAP CAR T-cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Coeptis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GPX-002

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Genprex

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh

                            Details : Under the agreement, Genprex gains a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to a gene therapy, GPX-002, for both Type 1 and Type 2 di...

                            Product Name : GPX-002

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 18, 2023

                            Lead Product(s) : GPX-002

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Genprex

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GPX-002

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Genprex

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pit...

                            Details : Diabetic mice studies have shown that GPX-002, a gene therapy for diabetes, restored normal blood glucose levels for an extended period of time, which could translate to decades in humans.

                            Product Name : GPX-002

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 15, 2022

                            Lead Product(s) : GPX-002

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Genprex

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PiN-21

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Low Doses of Inhalable 'nanobody' Fights Off Covid in Hamsters

                            Details : The treatment, dubbed PiN-21, could offer an affordable, needle-free option for treating early infections of SARS-CoV-2—the novel coronavirus behind COVID.

                            Product Name : PiN-21

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 26, 2021

                            Lead Product(s) : PiN-21

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery

                            Sponsor : Astellas Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Astellas, University of Pittsburgh Enter Research Collaboration for Dry Age-Related Macular Degeneration Treat...

                            Details : Cell Biology and Developmental Biology in University of Pittsburgh School of Medicine and Astellas will work jointly to evaluate and optimize the drug candidates with an aim to provide new treatment options to help recover and maintain vision in dry AMD ...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 24, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery

                            Sponsor : Astellas Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ab8

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pitt Scientists Discover Tiny Antibody Component That is Highly Effective in Preventing and Treating SARS-CoV-...

                            Details : The researchers reported in the journal Cell that Ab8 is highly effective in preventing and treating SARS-CoV-2 infection in mice and hamsters. In mice and hamsters, Ab8 proved effective in preventing and treating the disease; the journal Cell published ...

                            Product Name : Ab8

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 14, 2020

                            Lead Product(s) : Ab8

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GPX-002

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $2.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NIH Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Li...

                            Details : The grant will assist Dr. Gittes’s development for his research project titled, “Alpha Cell Conversion to Beta Cells in Non-human Primates” and will build upon his accumulating groundbreaking gene therapy work toward finding a cure for diabetes.

                            Product Name : GPX-002

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 21, 2020

                            Lead Product(s) : GPX-002

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $2.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SARS-CoV-2 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            University of Pittsburgh To Begin Work on Novel Coronavirus Vaccine

                            Details : Pitt center formed a coronavirus task force and is pursuing the live virus from the U.S. Centers for Disease Control and Prevention to develop disease models that will support vaccine development.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 13, 2020

                            Lead Product(s) : SARS-CoV-2 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Undisclosed

                            Sponsor : CSL Behring

                            Deal Size : $0.2 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            University City Science Center inks partnership with CSL Behring

                            Details : Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            February 13, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : CSL Behring

                            Deal Size : $0.2 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PittCoVacc

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            COVID-19 Vaccine Candidate Shows Immune Response in Early Testing

                            Details : When tested in mice, PittCoVacc, delivered through a fingertip-sized patch, produces antibodies specific to SARS-CoV-2 at quantities thought to be sufficient for neutralizing the virus.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 04, 2020

                            Lead Product(s) : PittCoVacc

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth